• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期淋巴结阴性乳腺癌的风险指数

A risk index for early node-negative breast cancer.

作者信息

Boyages J, Taylor R, Chua B, Ung O, Bilous M, Salisbury E, Wilcken N

机构信息

New South Wales Breast Cancer Institute, Westmead, New South Wales, Australia.

出版信息

Br J Surg. 2006 May;93(5):564-71. doi: 10.1002/bjs.5207.

DOI:10.1002/bjs.5207
PMID:16607692
Abstract

BACKGROUND

This study compared the application of the St Gallen 2001 classification with a risk index developed at the New South Wales Breast Cancer Institute (BCI Index) for women with node-negative breast cancer treated without adjuvant systemic therapy.

METHODS

The BCI risk categories were constructed by identifying combinations of prognostic indicators that produced homogeneous low-, intermediate- and high-risk groups using the same variables as in the St Gallen classification.

RESULTS

The BCI low-risk category consisted of women aged 35 years or more with a grade 1 oestrogen receptor (ER)-positive tumour 20 mm or less in diameter, or with a grade 2 ER-positive tumour of 15 mm or less. This category constituted 40.1 per cent of patients, with a 10-year distant relapse-free survival (DRFS) rate of 97.2 per cent. The BCI intermediate-risk category included women aged 35 years or more with a grade 2 ER-positive tumour of diameter 16-20 mm, or a grade 1 or 2 ER-negative tumour measuring 15 mm or less, and comprised 12.1 per cent of the women, with a 10-year DRFS rate of 88 per cent. The high-risk category comprised 47.7 per cent of women, with a 10-year DRFS rate of 68.4 per cent.

CONCLUSION

If confirmed in other data sets, the BCI Index may be used to identify women at low risk of distant relapse (2.8 per cent at 10 years) who are unlikely to benefit from adjuvant systemic therapy, and women at intermediate risk of distant relapse (12 per cent at 10 years) in whom the benefit of adjuvant systemic therapy is small.

摘要

背景

本研究比较了圣加仑2001年分类法与新南威尔士州乳腺癌研究所制定的风险指数(BCI指数)在未接受辅助全身治疗的淋巴结阴性乳腺癌女性中的应用。

方法

BCI风险类别是通过识别预后指标的组合构建而成的,这些组合使用与圣加仑分类法相同的变量产生了同质的低、中、高风险组。

结果

BCI低风险类别包括年龄35岁及以上、肿瘤直径20毫米及以下的1级雌激素受体(ER)阳性肿瘤患者,或直径15毫米及以下的2级ER阳性肿瘤患者。该类别占患者的40.1%,10年远处无复发生存率(DRFS)为97.2%。BCI中风险类别包括年龄35岁及以上、直径16 - 20毫米的2级ER阳性肿瘤患者,或直径15毫米及以下的1级或2级ER阴性肿瘤患者,占女性患者的12.1%,10年DRFS率为88%。高风险类别占女性患者的47.7%,10年DRFS率为68.4%。

结论

如果在其他数据集中得到证实,BCI指数可用于识别远处复发风险低(10年时为2.8%)、不太可能从辅助全身治疗中获益的女性,以及远处复发风险中等(10年时为12%)、辅助全身治疗获益较小的女性。

相似文献

1
A risk index for early node-negative breast cancer.早期淋巴结阴性乳腺癌的风险指数
Br J Surg. 2006 May;93(5):564-71. doi: 10.1002/bjs.5207.
2
Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy.对淋巴结阴性乳腺癌患者使用圣加仑分类法可能会导致辅助化疗的过度使用。
Br J Surg. 2002 Jun;89(6):789-96. doi: 10.1046/j.1365-2168.2002.02113.x.
3
Clinical outcome of breast conservation therapy for breast cancer in Hong Kong: prognostic impact of ipsilateral breast tumor recurrence and 2005 St. Gallen risk categories.香港乳腺癌保乳治疗的临床结果:同侧乳腺肿瘤复发及2005年圣加仑风险分类的预后影响。
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):667-72. doi: 10.1016/j.ijrobp.2006.12.043. Epub 2007 Mar 26.
4
Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.Ki-67表达为2007年圣加仑会议及辅助治疗!在线乳腺癌风险分类提供了额外的预后信息。
Ann Surg Oncol. 2009 May;16(5):1112-21. doi: 10.1245/s10434-009-0334-7. Epub 2009 Feb 14.
5
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.接受辅助性他莫昔芬治疗的雌激素受体阳性早期乳腺癌绝经后女性的早期复发风险。
Cancer. 2008 Apr 1;112(7):1437-44. doi: 10.1002/cncr.23320.
6
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.接受辅助他莫昔芬治疗的激素受体阳性绝经后乳腺癌患者早期远处复发的预后因素:一项回顾性分析结果
Cancer. 2007 Jun 1;109(11):2197-204. doi: 10.1002/cncr.22667.
7
Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.与保乳手术和全乳放疗后的无淋巴结转移患者相比,有1至3个阳性淋巴结的T1至T2期乳腺癌患者有更高的局部和区域复发风险。
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):357-64. doi: 10.1016/j.ijrobp.2008.04.034.
8
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.应用USC/范纽斯预后指数的259例乳腺导管原位癌患者:长期随访的回顾性研究
Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9.
9
Importance of routine cavity sampling in breast conservation surgery.保乳手术中常规切缘取样的重要性。
Br J Surg. 2009 Jan;96(1):47-53. doi: 10.1002/bjs.6435.
10
Effectiveness of radiation therapy for older women with early breast cancer.放射治疗对老年早期乳腺癌女性患者的疗效
J Natl Cancer Inst. 2006 May 17;98(10):681-90. doi: 10.1093/jnci/djj186.

引用本文的文献

1
The added value of ultrasound imaging biomarkers to clinicopathological factors for the prediction of high-risk Oncotype DX recurrence scores in patients with breast cancer.超声成像生物标志物对乳腺癌患者高风险Oncotype DX复发评分预测中临床病理因素的附加值。
Quant Imaging Med Surg. 2024 May 1;14(5):3519-3533. doi: 10.21037/qims-23-1620. Epub 2024 Apr 26.
2
Mammography-based radiomics for predicting the risk of breast cancer recurrence: a multicenter study.基于乳腺 X 线摄影的放射组学预测乳腺癌复发风险:一项多中心研究。
Br J Radiol. 2021 Nov 1;94(1127):20210348. doi: 10.1259/bjr.20210348. Epub 2021 Sep 14.
3
Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer.
新诊断乳腺癌中的循环肿瘤细胞、疾病复发与生存情况
Breast Cancer Res. 2012 Oct 22;14(5):R133. doi: 10.1186/bcr3333.
4
Node-Negative Breast Cancer: Which Patients Should Be Treated?淋巴结阴性乳腺癌:哪些患者应接受治疗?
Breast Care (Basel). 2008;3(4):237-243. doi: 10.1159/000149357. Epub 2008 Aug 20.
5
Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.联合使用 ER/PR/HER2 亚型和 2007 年圣加仑共识声明进行早期乳腺癌治疗。
BMC Cancer. 2010 May 21;10:228. doi: 10.1186/1471-2407-10-228.